RenovoRx, Inc. Common Stock
RNXT
RNXT: RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 pancreatic cancer clinical trial for its lead product candidate RenovoGem.
moreShow RNXT Financials
Recent trades of RNXT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by RNXT's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods for delivery of therapeutic materials to treat cancer Jan. 03, 2023
-
Patent Title: Methods for treating cancerous tumors Jul. 06, 2021
-
Patent Title: Methods for treating cancerous tumors Jun. 30, 2020
-
Patent Title: Methods for delivery of therapeutic materials to treat pancreatic cancer Dec. 24, 2019
-
Patent Title: Occlusion catheter system and methods of use Oct. 16, 2018
-
Patent Title: Devices, methods and kits for delivery of therapeutic materials to a pancreas Oct. 11, 2016
-
Patent Title: Devices, methods and kits for delivery of therapeutic materials to a target artery Oct. 04, 2016
-
Patent Title: Devices, methods and kits for delivery of therapeutic materials to a pancreas Sep. 02, 2014
Federal grants, loans, and purchases
Followers on RNXT's company Twitter account
Number of mentions of RNXT in WallStreetBets Daily Discussion
Recent insights relating to RNXT
Recent picks made for RNXT stock on CNBC
ETFs with the largest estimated holdings in RNXT
Flights by private jets registered to RNXT